Prospective Grant of Exclusive License: Development of the CB1/iNOS Series of Compounds as a Therapeutic To Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans, 22995 [2016-08985]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 75 / Tuesday, April 19, 2016 / Notices
Dated: April 8, 2016.
Elizabeth A. Fowler,
Deputy Director for Management Operations
Indian Health Service.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jerusalem, Israel. The patent rights in
these inventions have been assigned to
the United States of America. This
license may be worldwide. The field of
use may be limited to the use of the
Licensed Patent Rights to ‘‘develop the
CB1/iNOS series of compounds as a
therapeutic to treat systemic sclerosis,
scleroderma, and other skin fibrotic
diseases.’’
National Institutes of Health
under the Freedom of Information Act,
5 U.S.C. 552.
DATES:
[FR Doc. 2016–09012 Filed 4–18–16; 8:45 am]
BILLING CODE 4165–16–P
Prospective Grant of Exclusive
License: Development of the CB1/iNOS
Series of Compounds as a Therapeutic
To Treat System Sclerosis,
Scleroderma, and Other Skin Fibrotic
Diseases in Humans
National Institutes of Diabetes
and Digestive and Kidney Diseases,
Public Health Service, PHS, National
Institutes of Health.
ACTION: Notice.
AGENCY:
This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent license to
practice the following inventions
embodied in the following patent
applications, entitled ‘‘CB1 receptor
mediating compounds’’:
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
22995
1. U.S. Provisional Patent Application No.:
61/991,333, HHS Ref. No.: E–140–2014/
0–US–01, Filed: May 09, 2014
2. PCT Application No.: PCT/US2015/
029946, HHS Ref. No.: E–140–2014/0–
PCT–02, Filed: May 08, 2015
3. U.S. Provisional Patent Application No.:
61/725,949, HHS Ref. No.: E–282 –2012/
0–US–01, Filed: November 13, 2012
4. PCT Application No.: PCT/US2013/
069686, HHS Ref. No.: E–282 –2012/0–
PCT–02, Filed: November 12, 2013
5. U.S. Patent Application No.: 14/442,383,
HHS Ref. No.: E–282–2012/0–US–03,
Filed: May 12, 2015
6. Canadian Patent Application No.: 2889697,
HHS Ref. No.: E–282–2012/0–CA–04,
Filed: April 27, 2015
7. European Patent Application No.:
13802153.0, HHS Ref. No.: E–282–2012/
0–EP–05, Filed: June 01, 2015
8. Indian Patent Application No.: 3733/
DELNP/2015, HHS Ref. No.: E–282–
2012/0–IN–06, Filed: May 01, 2015
9. Japanese Patent Application No.: 2015–
542015, HHS Ref. No.: E–282–2012/0–
JP–07, Filed: May 11, 2015
10. Chinese Patent Application No.:
201380069389.9, HHS Ref. No.: E–282–
2012/0–CN–08, Filed: July 3, 2015
11. US Provisional Application No.: 62/
171,179, HHS Ref. No.: E–282–2012/1–
US–01, Filed: June 04, 2015
to Vital Spark Inc., (‘‘Vital Spark’’), a
company incorporated under the laws of
Delaware and having an office in
VerDate Sep<11>2014
18:02 Apr 18, 2016
Jkt 238001
Only written comments and/or
applications for a license which are
received by the Technology
Advancement Office, The National
Institute of Diabetes and Digestive and
Kidney Diseases on or before May 4,
2016 will be considered.
ADDRESSES: Requests for copies of the
patent application, patents, inquiries,
comments, and other materials relating
to the contemplated exclusive license
should be directed to: Betty Tong, Ph.D.,
Sr. Licensing and Patenting Manager,
Technology Advancement Office, The
National Institute of Diabetes and
Digestive and Kidney Diseases, 12A
South Drive, Bethesda, MD 20892,
Email: betty.tong@nih.gov. A signed
confidentiality non-disclosure
agreement will be required to receive
copies of any patent applications that
have not been published by the United
States Patent and Trademark Office or
the World Intellectual Property
Organization.
This
technology, and its corresponding
patent applications, is directed to
methods of treating fibrosis, obesity and
associated diseases such as type 2
diabetes by administering an agent that
reduces appetite, body weight, hepatic
steatosis, and insulin resistance. This
technology may be useful as a means for
treating various fibrotic diseases and
metabolic syndromes without serious
adverse neuropsychiatric side effects.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the Technology
Advancement Office receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license in response to this notice
will be treated as objections to the
contemplated license. Comments and
objections submitted in response to this
notice will not be made available for
public inspection and, to the extent
permitted by law, will not be released
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Dated: April 13, 2016.
Anna Amar,
Acting Deputy Director, Technology
Advancement Office, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2016–08985 Filed 4–18–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–13–228:
Biomarkers for Diabetes and Kidney Diseases
using Biosamples from the NIDDK Repository
(R01).
Date: June 1, 2016.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contaact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
ROOM 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK–KUH
Fellowship Review.
Date: June 3, 2016.
Time: 8:00 a.m. to 9:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave. NW., Washington, DC 20037.
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard,
E:\FR\FM\19APN1.SGM
19APN1
]]>Agencies
[Federal Register Volume 81, Number 75 (Tuesday, April 19, 2016)]
[Notices]
[Page 22995]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08985]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of the CB1/
iNOS Series of Compounds as a Therapeutic To Treat System Sclerosis,
Scleroderma, and Other Skin Fibrotic Diseases in Humans
AGENCY: National Institutes of Diabetes and Digestive and Kidney
Diseases, Public Health Service, PHS, National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an exclusive
patent license to practice the following inventions embodied in the
following patent applications, entitled ``CB1 receptor mediating
compounds'':
1. U.S. Provisional Patent Application No.: 61/991,333, HHS Ref.
No.: E-140-2014/0-US-01, Filed: May 09, 2014
2. PCT Application No.: PCT/US2015/029946, HHS Ref. No.: E-140-2014/
0-PCT-02, Filed: May 08, 2015
3. U.S. Provisional Patent Application No.: 61/725,949, HHS Ref.
No.: E-282 -2012/0-US-01, Filed: November 13, 2012
4. PCT Application No.: PCT/US2013/069686, HHS Ref. No.: E-282 -
2012/0-PCT-02, Filed: November 12, 2013
5. U.S. Patent Application No.: 14/442,383, HHS Ref. No.: E-282-
2012/0-US-03, Filed: May 12, 2015
6. Canadian Patent Application No.: 2889697, HHS Ref. No.: E-282-
2012/0-CA-04, Filed: April 27, 2015
7. European Patent Application No.: 13802153.0, HHS Ref. No.: E-282-
2012/0-EP-05, Filed: June 01, 2015
8. Indian Patent Application No.: 3733/DELNP/2015, HHS Ref. No.: E-
282-2012/0-IN-06, Filed: May 01, 2015
9. Japanese Patent Application No.: 2015-542015, HHS Ref. No.: E-
282-2012/0-JP-07, Filed: May 11, 2015
10. Chinese Patent Application No.: 201380069389.9, HHS Ref. No.: E-
282-2012/0-CN-08, Filed: July 3, 2015
11. US Provisional Application No.: 62/171,179, HHS Ref. No.: E-282-
2012/1-US-01, Filed: June 04, 2015
to Vital Spark Inc., (``Vital Spark''), a company incorporated under
the laws of Delaware and having an office in Jerusalem, Israel. The
patent rights in these inventions have been assigned to the United
States of America. This license may be worldwide. The field of use may
be limited to the use of the Licensed Patent Rights to ``develop the
CB1/iNOS series of compounds as a therapeutic to treat systemic
sclerosis, scleroderma, and other skin fibrotic diseases.''
DATES: Only written comments and/or applications for a license which
are received by the Technology Advancement Office, The National
Institute of Diabetes and Digestive and Kidney Diseases on or before
May 4, 2016 will be considered.
ADDRESSES: Requests for copies of the patent application, patents,
inquiries, comments, and other materials relating to the contemplated
exclusive license should be directed to: Betty Tong, Ph.D., Sr.
Licensing and Patenting Manager, Technology Advancement Office, The
National Institute of Diabetes and Digestive and Kidney Diseases, 12A
South Drive, Bethesda, MD 20892, Email: betty.tong@nih.gov. A signed
confidentiality non-disclosure agreement will be required to receive
copies of any patent applications that have not been published by the
United States Patent and Trademark Office or the World Intellectual
Property Organization.
SUPPLEMENTARY INFORMATION: This technology, and its corresponding
patent applications, is directed to methods of treating fibrosis,
obesity and associated diseases such as type 2 diabetes by
administering an agent that reduces appetite, body weight, hepatic
steatosis, and insulin resistance. This technology may be useful as a
means for treating various fibrotic diseases and metabolic syndromes
without serious adverse neuropsychiatric side effects.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within fifteen
(15) days from the date of this published notice, the Technology
Advancement Office receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license in response to
this notice will be treated as objections to the contemplated license.
Comments and objections submitted in response to this notice will not
be made available for public inspection and, to the extent permitted by
law, will not be released under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 13, 2016.
Anna Amar,
Acting Deputy Director, Technology Advancement Office, National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health.
[FR Doc. 2016-08985 Filed 4-18-16; 8:45 am]
BILLING CODE 4140-01-P
